The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...

Compass Pathways hopes to submit an NDA in Q4 leading up to potential approval.

Compass Pathways shares surged Tuesday after the company said its psilocybin therapy for depression met its primarily goals in recent trials. Shares traded 34% higher ahead of the morning bell at ...

By Sahil Pandey and Christy Santhosh Feb 17 (Reuters) - Compass Pathways said on Tuesday its psilocybin-based therapy eased depression symptoms in a late-stage trial, sending the drug developer's ...

Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical Officer Guy Goodwin. By providing 26 weeks’ worth of such data instead of the ...

The latest readout, from the COMP006 study, showed that two doses of the highest, 25mg dose of COMP360, given in a controlled environment with psychological support from a trained therapist, were ...

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis. Read more on CMPS stock here.

According to InvestmentNews, the panel’s award included about $5.375 million in compensatory damages plus $125,000 in costs.